Literature DB >> 24042462

Contextual effect of repression of bone morphogenetic protein activity in prostate cancer.

Linda Kim Pham1, Mengmeng Liang, Helty A Adisetiyo, Chun-Peng Liao, Michael B Cohen, Stanley M Tahara, Baruch Frenkel, Noriyuki Kasahara, Pradip Roy-Burman.   

Abstract

Several studies have focused on the effect of bone morphogenetic protein (BMP) on prostate cancer homing and growth at distant metastatic sites, but very little effect at the primary site. Here, we used two cell lines, one (E8) isolated from a primary tumor and the other (cE1) from a recurrent tumor arising at the primary site, both from the conditional Pten deletion mouse model of prostatic adenocarcinoma. Over-expression of the BMP antagonist noggin inhibited proliferation of cE1 cells in vitro while enhancing their ability to migrate. On the other hand, cE1/noggin grafts grown in vivo showed a greater mass and a higher proliferation index than the cE1/control grafts. For suppression of BMP activity in the context of cancer-associated fibroblasts (CAFs), we used noggin-transduced CAFs from the same mouse model to determine their effect on E8- or cE1-induced tumor growth. CAF/noggin led to increased tumor mass and greater de-differentiation of the E8 cell when compared with tumors formed in the presence of CAF/control cells. A trend of increase in the size of the tumor was also noted for cE1 cells when inoculated with CAF/noggin. Together, the results may point to a potential inhibitory role of BMP in the growth or re-growth of prostate tumor at the primary site. Additionally, results for cE1/noggin, and cE1 mixed with CAF/noggin, suggested that suppression of BMP activity in the cancer cells may have a stronger growth-enhancing effect on the tumor than its suppression in the fibroblastic compartment of the tumor microenvironment.

Entities:  

Keywords:  BMP; cancer-associated fibroblasts; noggin; prostate cancer cell lines; prostate cancer mouse model

Mesh:

Substances:

Year:  2013        PMID: 24042462      PMCID: PMC3885249          DOI: 10.1530/ERC-13-0100

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  39 in total

1.  Structural basis of BMP signalling inhibition by the cystine knot protein Noggin.

Authors:  Jay Groppe; Jason Greenwald; Ezra Wiater; Joaquin Rodriguez-Leon; Aris N Economides; Witek Kwiatkowski; Markus Affolter; Wylie W Vale; Juan Carlos Izpisua Belmonte; Senyon Choe
Journal:  Nature       Date:  2002-12-12       Impact factor: 49.962

2.  Expression of bone morphogenetic protein receptors type-IA, -IB and -II correlates with tumor grade in human prostate cancer tissues.

Authors:  I Y Kim; D H Lee; H J Ahn; H Tokunaga; W Song; L M Devereaux; D Jin; T K Sampath; R A Morton
Journal:  Cancer Res       Date:  2000-06-01       Impact factor: 12.701

3.  FGF18 represses noggin expression and is induced by calcineurin.

Authors:  Martina I Reinhold; Makoto Abe; Ravi M Kapadia; Zhixiang Liao; Michael C Naski
Journal:  J Biol Chem       Date:  2004-07-13       Impact factor: 5.157

4.  Noggin and sclerostin bone morphogenetic protein antagonists form a mutually inhibitory complex.

Authors:  David G Winkler; Changpu Yu; James C Geoghegan; Ethan W Ojala; John E Skonier; Diana Shpektor; May K Sutherland; John A Latham
Journal:  J Biol Chem       Date:  2004-06-14       Impact factor: 5.157

5.  Vascular endothelial growth factor contributes to the prostate cancer-induced osteoblast differentiation mediated by bone morphogenetic protein.

Authors:  Jinlu Dai; Yasuhide Kitagawa; Jian Zhang; Zhi Yao; Atsushi Mizokami; Shiyuan Cheng; Jacques Nör; Laurie K McCauley; Russell S Taichman; Evan T Keller
Journal:  Cancer Res       Date:  2004-02-01       Impact factor: 12.701

6.  Expression of bone morphogenetic protein-7 (BMP-7) in human prostate.

Authors:  Hiroshi Masuda; Yoshitatsu Fukabori; Katsuya Nakano; Nobuaki Shimizu; Hidetoshi Yamanaka
Journal:  Prostate       Date:  2004-04-01       Impact factor: 4.104

7.  The prognostic significance of BMP-6 signaling in prostate cancer.

Authors:  Hiu-Fung Yuen; Yuen-Piu Chan; Wai-Lok Cheung; Yong-Chuan Wong; Xianghong Wang; Kwok-Wah Chan
Journal:  Mod Pathol       Date:  2008-10-17       Impact factor: 7.842

8.  A third-generation lentivirus vector with a conditional packaging system.

Authors:  T Dull; R Zufferey; M Kelly; R J Mandel; M Nguyen; D Trono; L Naldini
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

9.  Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery.

Authors:  R Zufferey; T Dull; R J Mandel; A Bukovsky; D Quiroz; L Naldini; D Trono
Journal:  J Virol       Date:  1998-12       Impact factor: 5.103

Review 10.  Comparative genomic analysis of the eight-membered ring cystine knot-containing bone morphogenetic protein antagonists.

Authors:  Orna Avsian-Kretchmer; Aaron J W Hsueh
Journal:  Mol Endocrinol       Date:  2003-10-02
View more
  5 in total

Review 1.  Strategies to avoid treatment-induced lineage crisis in advanced prostate cancer.

Authors:  Guilhem Roubaud; Bobby C Liaw; William K Oh; David J Mulholland
Journal:  Nat Rev Clin Oncol       Date:  2016-11-22       Impact factor: 66.675

2.  Identification of Androgen Receptor Splice Variants in the Pten Deficient Murine Prostate Cancer Model.

Authors:  Mengmeng Liang; Helty Adisetiyo; Xiuqing Li; Xiuqing Liu; Ren Liu; Parkash Gill; Pradip Roy-Burman; Jeremy O Jones; David J Mulholland
Journal:  PLoS One       Date:  2015-07-21       Impact factor: 3.240

Review 3.  MicroRNA binding site polymorphisms as biomarkers in cancer management and research.

Authors:  Monica Cipollini; Stefano Landi; Federica Gemignani
Journal:  Pharmgenomics Pers Med       Date:  2014-07-23

4.  Exosomes Released by Gastric Cancer Cells Induce Transition of Pericytes Into Cancer-Associated Fibroblasts.

Authors:  Xiaofei Ning; Hongran Zhang; Cong Wang; Xiuqi Song
Journal:  Med Sci Monit       Date:  2018-04-18

Review 5.  Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer.

Authors:  Fanglong Wu; Jin Yang; Junjiang Liu; Ye Wang; Jingtian Mu; Qingxiang Zeng; Shuzhi Deng; Hongmei Zhou
Journal:  Signal Transduct Target Ther       Date:  2021-06-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.